SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
91,500
-900 (-0.97%)
Last updated: Jun 26, 2025

SK Biopharmaceuticals Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
7,126,5068,700,6027,862,6505,646,3857,612,04813,234,939
Upgrade
Market Cap Growth
8.29%10.66%39.25%-25.82%-42.48%-
Upgrade
Enterprise Value
7,006,4148,637,7347,807,6055,442,3047,267,51612,840,764
Upgrade
Last Close Price
91000.00111100.00100400.0072100.0097200.00169000.00
Upgrade
PE Ratio
28.3736.14--117.39-
Upgrade
Forward PE
41.9073.81----
Upgrade
PS Ratio
12.3315.8922.1622.9418.18509.06
Upgrade
PB Ratio
12.0515.1624.5017.8417.1434.92
Upgrade
P/TBV Ratio
12.7716.2429.5918.8617.9036.83
Upgrade
P/FCF Ratio
72.4693.05----
Upgrade
P/OCF Ratio
71.4391.68----
Upgrade
EV/Sales Ratio
12.1215.7722.0022.1117.36493.89
Upgrade
EV/EBITDA Ratio
70.6675.93--68.18-
Upgrade
EV/EBIT Ratio
86.0089.66--76.53-
Upgrade
EV/FCF Ratio
71.2392.38----
Upgrade
Debt / Equity Ratio
0.210.320.560.490.040.05
Upgrade
Debt / EBITDA Ratio
0.961.62--0.15-
Upgrade
Debt / FCF Ratio
1.271.97----
Upgrade
Asset Turnover
0.650.620.510.380.730.08
Upgrade
Inventory Turnover
0.370.400.350.530.600.13
Upgrade
Quick Ratio
1.341.261.472.282.645.67
Upgrade
Current Ratio
1.841.642.022.993.186.16
Upgrade
Return on Equity (ROE)
50.86%50.72%-11.10%-36.66%15.75%-135.18%
Upgrade
Return on Assets (ROA)
7.79%6.84%-3.38%-12.53%10.38%-46.83%
Upgrade
Return on Capital (ROIC)
11.07%9.58%-4.83%-17.57%13.84%-60.65%
Upgrade
Return on Capital Employed (ROCE)
16.60%15.00%--19.20%-
Upgrade
Earnings Yield
3.53%2.77%-0.42%-2.47%0.85%-1.87%
Upgrade
FCF Yield
1.38%1.07%-1.23%-2.92%-1.28%-1.68%
Upgrade
Buyback Yield / Dilution
-----9.12%-10.41%
Upgrade
Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.